Company Of The Day: Merck
What?
Merck (NYSE:MRK) is preparing a new formulation for its blockbuster cancer immunotherapy Keytruda, which could be injected under the skin.
Why?
- Here’s What To Expect From Merck’s Q4
- Pick Either Merck Stock Or Its Peer – Both May Offer Similar Returns
- Is A Fall Imminent For Merck Stock After A 12% Rise In A Month?
- Will Merck Stock Rise After Its Q3 Results?
- Merck Stock Is Likely A Better Pick Over Its Peer
- Is Humira Maker A Better Bet Over Merck Stock?
Keytruda will see patents start to expire in 2028. Merck believes that the new formulation has the potential to be novel, non-obvious, and useful, implying that it could receive a new patent.
So What?
Keytruda is Merck’s most important drug, generating over $17 billion in sales in 2021. These developments could potentially help the company hold off on a sales decline.
See Our Complete Analysis For Merck
| Returns | Dec 2022 MTD [1] |
2022 YTD [1] |
2017-22 Total [2] |
| MRK Return | 0% | 44% | 87% |
| S&P 500 Return | 0% | -15% | 82% |
| Trefis Multi-Strategy Portfolio | 1% | -17% | 230% |
[1] Month-to-date and year-to-date as of 12/5/2022
[2] Cumulative total returns since the end of 2016